Measures of Morbidity: Functional Assessment and Cytokines

Biology of Blood and Marrow Transplantation

Volumn 13, Issue SUPPL. 1, 2007, Pages 98-102

  Giralt, Sergio ^a   Simmonds, Maureen ^b   Smith, Roy ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Functional status; Growth hormone agonists; Progenitor cell transplantation

Indexed keywords

3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; ALENDRONIC ACID; CYTOKINE; IBUTAMOREN; MK 667; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GERIATRIC DISORDER; GERIATRIC PATIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MONOTHERAPY; MORBIDITY; MORTALITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PREDICTION; PROTEIN FUNCTION; QUALITY OF LIFE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33845968836     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.10.014     Document Type: Article

References (39)

1. Bolwell B.J. Are predictive factors clinically useful in bone marrow transplantation?. Bone Marrow Transplantation 32 (2003) 853-861
2. Fujimaki K., Maruta A., Yoshida M., et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 27 (2001) 307-310
3. Hertenstein B., Stefanic M., Schmeiser T., et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 12 (1994) 998-1004
4. Jain B., Floreani A.A., Anderson J.R., et al., The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. Bone Marrow Transplant 17 (1996) 561-568
5. Lehmann S., Isberg B., Ljungman P., and Paul C. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 26 (2000) 187-192
6. Goldberg S.L., Klumpp T.R., Magdalinski A.J., et al. Value of the pretransplant evaluation in predicting toxic 100-day mortality among blood stem cell and bone marrow recipients. J Clin Oncol 16 (1998) 3796-3802
7. Chien J.W., Madtes D.K., and Clark J.G. Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 35 (2005) 429-435
8. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
9. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 64 (2000) 281-291
10. Karnofsky D.A., and Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod C.M. (Ed). Evaluation of Chemotherapeutic Agents (1949), Columbia University Press, New York 191-205
11. Zubrod C. Clinical investigations in cancer chemotherapy. J Chronic Dis 8 (1958) 183-190
12. Weisdorf D., Bishop M., Dharan B., et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Bloood Marrow Transplant 8 (2002) 213-220
13. Robin M., Guardiola P., Dombret H., et al. Allogeneic bone marrow transplantation for acute myeloblastic leukemia in remission: risk factors for long term morbidity and mortality. Bone Marrow Transplant 31 (2003) 877-887
14. Deeg H.J., Seidel K., Bruemmer B., et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 15 (1995) 461-468
15. de Groot V., Beckerman H., Lankhorst G.J., and Bouter L.M. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56 (2003) 221-229
16. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 36 (2000) 453-471
17. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35 (2000) 181-200
18. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
19. Shahjahan M., Alamo J., de Lima M., et al. Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission. Biol Blood Marrow Transplant 10 suppl 2 (2004) 12-13
20. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
21. Sorror M., Maris M., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
22. Pollyea D., Artz A., Stock W., et al. Clinical predictors of transplant related mortality after reduced intensity allogeneic stem cell. Blood 104 (2004) Abstract 1145
23. Sorror M.L., Giralt S., Sandmaier B., et al. Validation of the predictive power of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after allogeneic HCT. Biol Blood Marrow Transplant 12 (2006) 8-9 Abstract 20
24. Baron F., Storb R., Storer B., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 24 (2006) 4150-4157
25. Simmonds M.J., Novy D.M., and Sandoval R. The influence of pain and fatigue on physical performance and health status in ambulatory patients with HIV. Clin J Pain 21 (2005) 200-206
26. Simmonds M.J. Physical function in patients with cancer. Psychometric characteristics and clinical usefulness of a physical performance test battery. J Pain Sympt Manage 24 (2002) 404-414
27. Simmonds M.J. The effect of pain and illness on movement: assessment methods and their meanings. In: Giamberadino M. (Ed). Pain Clinical Update (2002), IASP Press, Seattle 179-187
28. Hall R.W., Hartman M.L., Veldhuis J.D., et al. Thirty-second sampling of plasma growth hormone (GH) in man: correlation with sleep stages. J Clin Endocrinol Metab 72 (1991) 854-861
29. Corpas E., Hartman S.M., and Blackman M.R. Human growth hormone and human aging. Endocr Rev 14 (1993) 20-39
30. Martin F.C., Yeo A., and Sonksen P.H. Growth hormone secretion in the elderly: ageing and the somatopause. Baillieres Clin Endocrinol Metab 11 (1997) 223-250
31. Khorram O. Use of growth hormone and growth hormone secretagogues in aging: help or harm. Clin Obstet Gynecol 44 (2001) 893-901
32. Rudman D., Feller A.G., Nagraj H.S., et al. Effects of human growth hormones in men over 60 years old. N Engl J Med 323 (1990) 1-6
33. Holloway L., Butterfield G., Hintz R.L., et al. Effects of recombinant growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 79 (1994) 470-479
34. Smith R. Development of growth hormone secretagogues. Endocr Rev 26 (2005) 346-360
35. Murphy M.G., Plunkett L.M., Gertz B.J., et al. MK-0677, an orally active growth hormone secretagogue reverses diet-induced catabolism. J Clin Endocrinol Metab 83 (1998) 320-325
36. Kirk S.E., Gertz B.J., Schneider S.H., et al. Effect of obesity and feeding on the growth hormone response to the GH secretagogue L-692,429 in young men. J Clin Endocrinol Metab 82 (1997) 1154-1159
37. Murphy M.G., Weiss S., McClung M., et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86 (2001) 1116-1125
38. Bach M.A., Rockwood K., Zetterberg C., et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 52 (2004) 516-552
39. Blum A., Cannon R.O., Costello R., et al. Endocrine and lipid effects of oral l -arginine treatment in healthy postmenopausal women. J Lab Clin Med 135 (2000) 231-237